AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10799790 — intervention group
Group type: COMPARATOR
Intervention: Patients with advanced dementia
Number of subjects: 97
Study 8615323 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (5 mg ramipril)
Number of subjects: 0
Study 8615323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1729872 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Bruce protocol
Number of subjects: 32
Study 6373158 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen twice daily
Number of subjects: 226
Study 6373158 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 226
Study 30768429 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of electronic health record‐based clinical decision support (CDS) tools
Number of subjects: 0
Study 30768429 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30475912 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 4011
Study 30475912 — intervention group
Group type: COMPARATOR
Intervention: No GTN
Number of subjects: 4011
Study 30475912 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator reported events
Number of subjects: 4011
Study 26215167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit Body and Soul (FBAS)
Number of subjects: 604
Study 26215167 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 604
Study 24112747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (MLE)
Number of subjects: 790
Study 24112747 — intervention group
Group type: COMPARATOR
Intervention: Lateral episiotomy (LE)
Number of subjects: 790
Study 22397833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multi-component intervention in low-SES community
Number of subjects: 1102
Study 22397833 — intervention group
Group type: COMPARATOR
Intervention: Low-SES control community
Number of subjects: 1102
Study 22397833 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample (both intervention and control)
Number of subjects: 1102
Study 22397833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention effects on eating behaviour, physical activity, or screen-time
Number of subjects: 1102
Study 22397833 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction effects of age and gender
Number of subjects: 1102
Study 21154265 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (8 g/day)
Number of subjects: 30
Study 21154265 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline malate (3 g/day)
Number of subjects: 30
Study 16969378 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA diet
Number of subjects: 61
Study 16969378 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA diet
Number of subjects: 61
Study 16969378 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA diet
Number of subjects: 61
Study 16969378 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA group
Number of subjects: 61
Study 16969378 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA group
Number of subjects: 61
Study 16969378 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA group
Number of subjects: 61
Study 16253720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3603
Study 16253720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3603
Study 12121721 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 12121721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9469327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy plus radiation (50 Gy)
Number of subjects: 818
Study 9469327 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 818
Study 7883113 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular beef/pork insulin
Number of subjects: 13
Study 7883113 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 13
Study 2168836 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately noxious temperature (46 degrees C) applied to the contralateral hand for 2 minutes
Number of subjects: 9
Study 2168836 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.4 mg i.v.)
Number of subjects: 9
Study 2168836 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 31488484 — intervention group
Group type: EXPERIMENTAL
Intervention: Up to five video consultations conducted by a mental health specialist
Number of subjects: 50
Study 31488484 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual as provided by their general practitioner
Number of subjects: 50
Study 28417203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mailed print diet and exercise interventions
Number of subjects: 50
Study 25226336 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 11
Study 25226336 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing Climb (SC)
Number of subjects: 11
Study 25226336 — intervention group
Group type: COMPARATOR
Intervention: Seated
Number of subjects: 11
Study 25226336 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-high RPE
Number of subjects: 11
Study 25226336 — intervention group
Group type: EXPERIMENTAL
Intervention: High RPE
Number of subjects: 11
Study 23627714 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure for 30 minutes, 10 weekly visits; 192 millitesla peak‐to‐peak value
Number of subjects: 11
Study 23627714 — intervention group
Group type: COMPARATOR
Intervention: Non‐magnetized pads (sham) for 30 minutes, 10 weekly visits
Number of subjects: 11
Study 23627714 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure
Number of subjects: 11
Study 21823377 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine (15 ml of 0.5%)
Number of subjects: 90
Study 21823377 — intervention group
Group type: COMPARATOR
Intervention: Control (no epidural levobupivacaine)
Number of subjects: 90
Study 20368213 — intervention group
Group type: EXPERIMENTAL
Intervention: muraglitazar (0.5, 1.5, 5, 10, and 20 mg)
Number of subjects: 1477
Study 20368213 — intervention group
Group type: COMPARATOR
Intervention: pioglitazone (15 mg)
Number of subjects: 1477
Study 20368213 — intervention group
Group type: EXPERIMENTAL
Intervention: muraglitazar
Number of subjects: 1477
Study 20368213 — intervention group
Group type: COMPARATOR
Intervention: pioglitazone
Number of subjects: 1477
Study 17111783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin plus IFN alpha‐2b 5 MU/day for 1 month followed by IFN alpha‐2b 5 MU thrice weekly for 5 months (Group A)
Number of subjects: 175
Study 17111783 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin plus IFN alpha‐2b 5 MU thrice weekly for 6 months (Group B)
Number of subjects: 175
Study 17111783 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (Group A)
Number of subjects: 175
Study 15576968 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0
Study 15576968 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation dihydropyridinoline CCBs
Number of subjects: 0
Study 11727875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioptric training (powered flipper training)
Number of subjects: 13
Study 11727875 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (plano lens training)
Number of subjects: 13
Study 8981375 — intervention group
Group type: EXPERIMENTAL
Intervention: New stimuli presented in hierarchical perception task
Number of subjects: 2
Study 8981375 — intervention group
Group type: COMPARATOR
Intervention: Previous study with unilateral or bilateral presentation
Number of subjects: 2
Study 7956629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) insulin infusion via programmable implantable pumps
Number of subjects: 10
Study 7956629 — intervention group
Group type: COMPARATOR
Intervention: Multiple subcutaneous (SC) injections
Number of subjects: 10
Study 3555691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed grafts
Number of subjects: 215
Study 3555691 — intervention group
Group type: COMPARATOR
Intervention: In situ grafts
Number of subjects: 215
Study 3555691 — intervention group
Group type: COMPARATOR
Intervention: Reversed grafts and In situ grafts
Number of subjects: 215
Study 31113167 — intervention group
Group type: COMPARATOR
Intervention: Karydakis flap (KF group)
Number of subjects: 80
Study 31113167 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap (LF group)
Number of subjects: 80
Study 28330458 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised 1-year extensive aerobic exercise intervention (3 units of 45 min/week)
Number of subjects: 75
Study 28330458 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching and toning (non-aerobic) exercise (3 units of 45 min/week)
Number of subjects: 75
Study 28330458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study 25363423 — intervention group
Group type: COMPARATOR
Intervention: Continuous use of occlusal splints (29 nights continuously)
Number of subjects: 20
Study 25363423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent use of occlusal splints (used on the 1st‐7th, 15th‐21st, and 29th nights)
Number of subjects: 20
Study 23103453 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 1659
Study 23103453 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 1659
Study 23103453 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed training
Number of subjects: 1659
Study 21234629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment combining cognitive behavioural therapy (CBT), graded exercise therapy (GET), and pharmacological treatment
Number of subjects: 120
Study 21234629 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (exercise counselling and pharmacological treatment)
Number of subjects: 120
Study 19450101 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 1000
Study 19450101 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1000
Study 17179058 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an informational brochure
Number of subjects: 781
Study 17179058 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 781
Study 12666320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening programs
Number of subjects: 0
Study 11139971 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation (5, 10, 20, and 40 mA for 2 ms)
Number of subjects: 77
Study 11139971 — intervention group
Group type: COMPARATOR
Intervention: Nonstimulated complexes
Number of subjects: 77
Study 8976803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy plus calcium (Prempak C or Premarin 0.625 mg with 1 g calcium daily)
Number of subjects: 116
Study 8976803 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (1 g calcium daily)
Number of subjects: 116
Study 8976803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 116
Study 1309303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administered at 75 mg/m2 in 3-week cycles
Number of subjects: 60
Study 1309303 — intervention group
Group type: EXPERIMENTAL
Intervention: Less conventional schedules of cisplatin (exact dosages not specified)
Number of subjects: 60
Study 1309303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) total dose of 450 mg/m2 across all groups
Number of subjects: 60
Study 1309303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) administration
Number of subjects: 60
Study 6373830 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback (N = 70)
Number of subjects: 102
Study 6373830 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (N = 32)
Number of subjects: 102
Study 6373830 — intervention group
Group type: COMPARATOR
Intervention: Cognitive structure measure
Number of subjects: 102
Study 6373830 — intervention group
Group type: COMPARATOR
Intervention: Mixed headache patients
Number of subjects: 102
Study 29667066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg
Number of subjects: 0
Study 29667066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg
Number of subjects: 0
Study 29667066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 mg
Number of subjects: 0
Study 25773465 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.6% menthol gel
Number of subjects: 10
Study 25773465 — intervention group
Group type: COMPARATOR
Intervention: 0.5% menthol gel
Number of subjects: 10
Study 25773465 — intervention group
Group type: COMPARATOR
Intervention: 10.0% menthol gel
Number of subjects: 10
Study 25576682 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting heart rate (HR) ≥70 bpm in younger patients
Number of subjects: 327
Study 25576682 — intervention group
Group type: COMPARATOR
Intervention: Lower resting heart rate (HR) <70 bpm in younger patients
Number of subjects: 327
Study 25576682 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting heart rate (HR) in older patients
Number of subjects: 327
Study 25576682 — intervention group
Group type: COMPARATOR
Intervention: Lower resting heart rate (HR) in older patients
Number of subjects: 327
Study 25104263 — intervention group
Group type: COMPARATOR
Intervention: FC2
Number of subjects: 600
Study 25104263 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman's Condom
Number of subjects: 600
Study 25104263 — intervention group
Group type: EXPERIMENTAL
Intervention: VA wow
Number of subjects: 600
Study 25104263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupid
Number of subjects: 600
Study 21903710 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (asana, pranayam, and meditation) for three months
Number of subjects: 0
Study 21903710 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 0
Study 17483128 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 7329
Study 17483128 — intervention group
Group type: COMPARATOR
Intervention: Non-users of digitalis
Number of subjects: 7329
Study 17033530 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 to 75 g/day milk-based fortified spreads
Number of subjects: 126
Study 17033530 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented controls (0 to 5 g FS)
Number of subjects: 126
Study 15208230 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD‐aide
Number of subjects: 149
Study 15208230 — intervention group
Group type: COMPARATOR
Intervention: 4Hs+4Ts
Number of subjects: 149
Study 10710119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/day)
Number of subjects: 454
Study 10710119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/day) + Bezafibrate (400 mg/day)
Number of subjects: 454
Study 9094876 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycogen (HG) treatment
Number of subjects: 8
Study 9094876 — intervention group
Group type: COMPARATOR
Intervention: Low glycogen (LG) treatment
Number of subjects: 8
Study 8386421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops
Number of subjects: 207
Study 8386421 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 207
Study 8386421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops and astemizole combined
Number of subjects: 207
Study 8386421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium alone or combined
Number of subjects: 207
Study 8386421 — intervention group
Group type: COMPARATOR
Intervention: Astemizole alone
Number of subjects: 207
Study 3092661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms twice daily)
Number of subjects: 93
Study 3092661 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 93
Study 3092661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 93
Study 3092661 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 93
Study 3092661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 93
Study 28332886 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler®
Number of subjects: 516
Study 28332886 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiromax®
Number of subjects: 516
Study 27353456 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 88
Study 23718572 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of FIB
Number of subjects: 20
Study 23718572 — intervention group
Group type: COMPARATOR
Intervention: 1 unit of apheresis PLTs
Number of subjects: 20
Study 22854310 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (titrated up to 60 mg daily or maximum tolerated dose, 48 days)
Number of subjects: 12
Study 22854310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (48 days)
Number of subjects: 12
Study 20044530 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril plus indapamide for those without contraindications)
Number of subjects: 6105
Study 20044530 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6105
Study 17594201 — intervention group
Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered alone
Number of subjects: 20
Study 17594201 — intervention group
Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg with Al-Mg antacid
Number of subjects: 20
Study 17594201 — intervention group
Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 2 hours after Al-Mg antacid
Number of subjects: 20
Study 17594201 — intervention group
Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 4 hours after Al-Mg antacid
Number of subjects: 20
Study 17594201 — intervention group
Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 4 hours before Al-Mg antacid
Number of subjects: 20
Study 17594201 — intervention group
Group type: EXPERIMENTAL
Intervention: garenoxacin 600 mg administered 2 hours before Al-Mg antacid
Number of subjects: 20
Study 16170978 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate MicroSonic battery-powered toothbrush
Number of subjects: 39
Study 16170978 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Indicator manual toothbrush
Number of subjects: 39
Study 11781970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ni-Cr-Be, chemically etched
Number of subjects: 63
Study 11781970 — intervention group
Group type: COMPARATOR
Intervention: Au-Pd, airborne particle-abraded and tin-plated
Number of subjects: 63
Study 11781970 — intervention group
Group type: EXPERIMENTAL
Intervention: Au-Pd, airborne particle-abraded and treated with Alloy Primer
Number of subjects: 63
Study 9264478 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (PTCA or CABG)
Number of subjects: 1008
Study 9264478 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 1008
Study 8497491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) capsules (15 x 1 g/d)
Number of subjects: 35
Study 8497491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PO) capsules (15 x 1 g/d)
Number of subjects: 35
Study 2433409 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 232
Study 2433409 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 232
Study 2433409 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 232
Study 2433409 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 232
Study 28884969 — intervention group
Group type: EXPERIMENTAL
Intervention: New procaterol dry powder inhaler (20 μg)
Number of subjects: 16
Study 28884969 — intervention group
Group type: COMPARATOR
Intervention: Approved procaterol dry powder inhaler (20 μg)
Number of subjects: 16
Study 27443162 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model of dose estimates based on current and prior INRs
Number of subjects: 556
Study 27443162 — intervention group
Group type: COMPARATOR
Intervention: GIFT algorithm (based on current INR)
Number of subjects: 556
Study 23272667 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation group (n=156)
Number of subjects: 1896
Study 23272667 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic group (n=179)
Number of subjects: 1896
Study 23272667 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1896
Study 23272667 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive participants (51.5% of screened)
Number of subjects: 1896
Study 23272667 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy participants subgroup (n=143)
Number of subjects: 1896
Study 21515899 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO set at 5° plantarflexion
Number of subjects: 8
Study 21515899 — intervention group
Group type: COMPARATOR
Intervention: AFO set at 5° dorsiflexion
Number of subjects: 8
Study 21515899 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO set at neutral alignment
Number of subjects: 8
Study 18473867 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 18473867 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 18473867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a provisional GP IIb/IIIa inhibitor
Number of subjects: 0
Study 18473867 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent PCI
Number of subjects: 0
Study 16433897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin administration (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Number of subjects: 20
Study 16433897 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin inhalation (67-100-150% of the regular heroin maintenance dose, max single dose 450 mg)
Number of subjects: 20
Study 16433897 — intervention group
Group type: COMPARATOR
Intervention: Both groups (inhaling and injecting)
Number of subjects: 20